Case Report: Clinical response to anaplastic lymphoma kinase inhibitor-based targeted therapy in uterine inflammatory myofibroblastic tumor harboring ALK-IGFBP5 fusion

BACKGROUND: An inflammatory myofibroblastic tumor (IMT) is a mesenchymal tumor with a prevalence ranging from 0.04% to 0.7% worldwide, in which the lung is the most common predilection site, accounting for 33% of cases, followed by the abdomen, pelvis, mesentery, and uterus. Approximately 50% of ute...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Ting, Zhang, Xiaowei, Liu, Xin, Ren, Min, Cheng, Yufan, Wang, Jian, Luo, Zhiguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076585/
https://www.ncbi.nlm.nih.gov/pubmed/37035208
http://dx.doi.org/10.3389/fonc.2023.1147974

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076585/
https://www.ncbi.nlm.nih.gov/pubmed/37035208
http://dx.doi.org/10.3389/fonc.2023.1147974

Ejemplares similares